DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Ladenstein R, Pötschger U, Valteau-Couanet D. et al.
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Lancet Oncol 2018;
19 (12) 1617-1629
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.